Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
27 pending office actions • 20 art units • 27 examiners • 0 of 27 (0%) have an AI response strategy ready • 17 patents granted in the last 365 days
The Children's Medical Center Corporation maintains a robust prosecution pipeline with 27 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 27 distinct examiners, meaning every pending matter is currently being reviewed by a different individual. This high level of examiner diversity is matched by a broad administrative reach across 20 distinct art units.
HIBBERT, CATHERINE S is the busiest examiner, though they only hold 1 pending office action. This highlights the extreme distribution of the pending office actions, as no single examiner handles more than one case. With 20 distinct art units involved, the portfolio spans a vast array of biological and pharmaceutical sub-specialties.
Practitioners must manage a complex array of examiner personalities and art unit specificities across this large volume of 27 actions. The lack of examiner overlap suggests that successful arguments in one case may not easily translate to others. Strategy must be tailored to the specific requirements of the distinct art units to ensure broad protection across the entire portfolio. This approach allows for a more granular defense of the company's intellectual property.
Based on the USPTO statutory response window for each pending office action. 9 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 9 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (7%) |
| §103 only | 5 (19%) |
| §112 only | 2 (7%) |
| Double-patenting + other | 5 (19%) |
| Multi-statute (no §101) | 13 (48%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HIBBERT, CATHERINE S | 1 | 58.9% | +48.8% |
| KASSA, TIGABU | 1 | 36.7% | +27.9% |
| GEIGER, RACHAEL L | 1 | 82.3% | +18.3% |
| PAULUS, ERIN VIRGINIA | 1 | 21.1% | +93.8% |
| AEDER, SEAN E | 1 | 57.0% | +19.9% |
| MARTIN, PAUL C | 1 | 41.8% | +21.6% |
| GABEL, GAILENE | 1 | 75.6% | +44.8% |
| GU, QINHUA | 1 | 75.9% | +27.8% |
| GOMES, SRISTI DIVINA | 1 | 25.0% | -33.3% |
| POLIAKOVA-GEORGAN, EKATERINA | 1 | 64.0% | +18.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17767340 | METHODS AND COMPOSITIONS FOR TREATING ATAXIA TELANGIECTASIA | MCLEOD, AFRICA MHAIRIE | 89d overdue |
| 18424292 | COMPOUNDS AND METHODS FOR TREATMENT OF DIAMOND BLACKFAN ANEMIA | PAULUS, ERIN VIRGINIA | 45d overdue |
| 18009645 | USE OF HEAT SHOCK PROTEIN INHIBITORS FOR THE TREATMENT OF NEURODEVELOPMENTAL DISORDERS | HUTTER, GILLIAN A | 1d overdue |
| 18320921 | SURGICAL REPAIR SIMULATION DEVICES | MCCLELLAN, JAMES S | 21d |
| 18703100 | SUBCUTANEOUS ABRASION TREATMENT FOR STRETCH MARKS | GEIGER, RACHAEL L | 54d |
| 18286405 | CARDIOMYOCYTES AND COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | MARTIN, PAUL C | 61d |
| 18716692 | COMPOSITIONS COMPRISING MODIFIED PHOSPHOLIPIDS AND USES THEREOF | KASSA, TIGABU | — |
| 18549676 | METHODS FOR DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE | GABEL, GAILENE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18424292 | COMPOUNDS AND METHODS FOR TREATMENT OF DIAMOND BLACKFAN ANEMIA | PAULUS, ERIN VIRGINIA | 45d overdue |
| 18703100 | SUBCUTANEOUS ABRASION TREATMENT FOR STRETCH MARKS | GEIGER, RACHAEL L | 54d |
| 18286405 | CARDIOMYOCYTES AND COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | MARTIN, PAUL C | 61d |
| 18835427 | COMPOSITIONS AND METHODS RELATING TO ATP/P2X7R SIGNALING INHIBITION | HIBBERT, CATHERINE S | — |
| 18716692 | COMPOSITIONS COMPRISING MODIFIED PHOSPHOLIPIDS AND USES THEREOF | KASSA, TIGABU | — |
| 18392902 | METHODS FOR DELIVERING ANTIBODIES TO THE FETAL CIRCULATION | AEDER, SEAN E | — |
| 18549676 | METHODS FOR DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE | GABEL, GAILENE | — |
| 18279336 | STROMA-FREE NK CELL DIFFERENTIATION FROM HUMAN PLURIPOTENT STEM CELLS | GU, QINHUA | — |
| Art Unit | Apps |
|---|---|
| 1631 | 3 |
| 1653 | 2 |
| 3715 | 2 |
| 1619 | 1 |
| 3771 | 1 |
| 1678 | 1 |
| 1633 | 1 |
| 3791 | 1 |
| 1637 | 1 |
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18835427 | COMPOSITIONS AND METHODS RELATING TO ATP/P2X7R SIGNALING INHIBITION | HIBBERT, CATHERINE S | — | §102§103§112DP | Non-Final OA | — | Pending | Aug 02, 2024 |
| 18716692 | COMPOSITIONS COMPRISING MODIFIED PHOSPHOLIPIDS AND USES THEREOF | KASSA, TIGABU | 1619 | §102§103 | Non-Final OA | — | Pending | Jun 05, 2024 |
| 18703100 | SUBCUTANEOUS ABRASION TREATMENT FOR STRETCH MARKS | GEIGER, RACHAEL L | 3771 | §102§103 | Non-Final OA | 54d | Pending | Apr 19, 2024 |
| 18424292 | COMPOUNDS AND METHODS FOR TREATMENT OF DIAMOND BLACKFAN ANEMIA | PAULUS, ERIN VIRGINIA | 1631 | §102§103§112 | Final Rejection | 45d overdue | Pending | Jan 26, 2024 |
| 18392902 | METHODS FOR DELIVERING ANTIBODIES TO THE FETAL CIRCULATION | AEDER, SEAN E | — | §103 | Final Rejection | — | Pending | Dec 21, 2023 |
| 18286405 | CARDIOMYOCYTES AND COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | MARTIN, PAUL C | 1653 | §102§103§112 | Non-Final OA | 61d | Pending | Oct 11, 2023 |
| 18549676 | METHODS FOR DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE | GABEL, GAILENE | 1678 | §101§102§103§112 | Non-Final OA | — | Pending | Sep 08, 2023 |
| 18279336 | STROMA-FREE NK CELL DIFFERENTIATION FROM HUMAN PLURIPOTENT STEM CELLS | GU, QINHUA | 1633 | §103§112Other | Non-Final OA | — | Pending | Aug 29, 2023 |
| 18236602 | SYSTEMS FOR ANALYZING PATTERNS IN ELECTRODERMAL ACTIVITY RECORDINGS OF PATIENTS TO PREDICT SEIZURE LIKELIHOOD AND METHODS OF USE THEREOF | GOMES, SRISTI DIVINA | 3791 | §101§103 | Final Rejection | — | Pending | Aug 22, 2023 |
| 18360505 | COMPOSITIONS AND METHODS FOR TREATING CEREBROSPINAL FLUID DISORDERS | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §102§103 | Non-Final OA | — | Pending | Jul 27, 2023 |
| 18352730 | COMPOSITIONS AND METHODS FOR NEUROPROTECTION AND/OR NEUROREGENERATION | CANDELARIA, JULIANA IRENE | 1634 | §103§112 | Non-Final OA | — | Pending | Jul 14, 2023 |
| 18341584 | COMPOSITIONS AND METHODS FOR TREATING DISEASES ASSOCIATED WITH AN IMPRINTING DEFECT | ANDERSON, JAMES D | 1629 | §112 | Non-Final OA | 171d overdue | Pending | Jun 26, 2023 |
| 18206830 | METHOD FOR TREATING CANCER | REGLAS, GEORGIANA C | 1651 | §103§112 | Non-Final OA | — | Pending | Jun 07, 2023 |
| 18320921 | SURGICAL REPAIR SIMULATION DEVICES | MCCLELLAN, JAMES S | 3715 | §102§103 | Non-Final OA | 21d | Pending | May 19, 2023 |
| 18320927 | SURGICAL REPAIR SIMULATION DEVICES | HULL, JAMES B | 3715 | §103 | Final Rejection | 28d overdue | Pending | May 19, 2023 |
| 18019627 | COMPOSITIONS FOR ALTERING A MICROGLIAL CELL, AND METHODS OF USE THEREFORE | SIMMONS, CHRIS E | 1622 | §102§112Other | Non-Final OA | — | Pending | Feb 03, 2023 |
| 18016190 | TARGETING ZNF410 FOR FETAL HEMOGLOBIN INDUCTION IN BETAHEMOGLOBINOPATHIES | VANHORN, ABIGAIL LOUISE | 1636 | §112DP | Non-Final OA | — | Pending | Jan 13, 2023 |
| 18005286 | NOVEL ANTI-PD1 ANTIBODIES FOR INHIBITING T-CELL ACTIVITY | CHASE, CAROL ANN | 1646 | §103DP | Non-Final OA | — | Pending | Jan 12, 2023 |
| 18002633 | METHODS AND COMPOSITIONS FOR TREATING MULTIPLE SCLEROSIS | KIM, TAEYOON | 1631 | §103DP | Final Rejection | — | Pending | Dec 20, 2022 |
| 18009645 | USE OF HEAT SHOCK PROTEIN INHIBITORS FOR THE TREATMENT OF NEURODEVELOPMENTAL DISORDERS | HUTTER, GILLIAN A | 1625 | §102§103 | Final Rejection | 1d overdue | Pending | Dec 09, 2022 |
| 18074107 | TARGETING BCL11A DISTAL REGULATORY ELEMENTS FOR FETAL HEMOGLOBIN REINDUCTION | MARVICH, MARIA | — | §112Other | Non-Final OA | — | Pending | Dec 02, 2022 |
| 17921802 | COMPOSITIONS AND METHODS OF PROMOTING MYELINATION | TICHY, JENNIFER M.H. | 1653 | §103 | Final Rejection | — | Pending | Oct 27, 2022 |
| 17794747 | STROMA-FREE T CELL DIFFERENTIATION FROM HUMAN PLURIPOTENT STEM CELLS | BEHARRY, ZANNA MARIA | 1632 | §103DP | Non-Final OA | — | Pending | Jul 22, 2022 |
| 17728927 | THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/Cas SYSTEMS | WILSON, MICHAEL C | 1638 | §103§112 | Final Rejection | — | Pending | Apr 25, 2022 |
| 17767340 | METHODS AND COMPOSITIONS FOR TREATING ATAXIA TELANGIECTASIA | MCLEOD, AFRICA MHAIRIE | 1635 | §102§103§112Other | Final Rejection | 89d overdue | Pending | Apr 07, 2022 |
| 17764413 | BCL11A GUIDE AND BASE EDITOR DELIVERY | HUMPHRIES, NICHOLAS ADAM | 1631 | §103 | Non-Final OA | 89d overdue | Pending | Mar 28, 2022 |
| 16806587 | METHODS AND PROCEDURES FOR LIGAMENT REPAIR | MANNAN, MIKAIL A | 3774 | §103 | Final Rejection | — | Pending | Mar 02, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial